SCHEMBL4019374

SCHEMBL4019374

CCCCCCCCCCCCNS(=O)(=O)c1ccc(C[CH]c2cccc(C(F)(F)F)c2)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
TSHR P16473 2/20 0.47
HTT P42858 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TRPV1 Q8NER1 1/20 0.38
IDH2 P48735 1/20 0.37
MAPT P10636 2/20 0.36
RECQL P46063 1/20 0.36
TP53 P04637 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
HDAC3 O15379 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
EPHX2 P34913 1/20 0.35
ALDH1A1 P00352 3/20 0.35
LMNA P02545 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4019801 1.00 MEN1 (0.47) MEN1KMT2ATSHRHTTSMN1; SMN2
SCHEMBL4017087 0.88 KMT2A (0.51) MEN1KMT2ATSHRHTTSMN1; SMN2
SCHEMBL4716661 0.84 MAPT (0.37) KMT2ATRPV1MAPTTP53ALDH1A1
SCHEMBL4714650 0.80 MEN1 (0.47) MEN1KMT2ATSHRHTTSMN1; SMN2
SCHEMBL4714646 0.80 TSHR (0.47) MEN1KMT2ATSHRHTTSMN1; SMN2
SCHEMBL4717989 0.80 MEN1 (0.47) MEN1KMT2ATSHRHTTSMN1; SMN2
SCHEMBL4717987 0.80 TSHR (0.47) MEN1KMT2ATSHRHTTSMN1; SMN2
SCHEMBL4018514 0.77 KMT2A (0.53) MEN1KMT2ATSHRHTTSMN1; SMN2
SCHEMBL4016045 0.75 SMN1; SMN2 (0.42) MEN1KMT2ATSHRHTTSMN1; SMN2
SCHEMBL1854854 0.75 SMN1; SMN2 (0.42) MEN1KMT2ATSHRHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections LABORATOIRES SERONO SA (CH) 2009-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections STS, TST, SULT1A1 MEN1 2947/4885KMT2A 2981/4885TSHR 1632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.